Abpro Holdings (ABPO) Profit After Tax (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Profit After Tax came in at -$1.0 million in Q1 2026, up 73.55% YoY from -$592326.7 in Q1 2025, and down 118.24% on a QoQ basis from $5.6 million in Q4 2025.
Abpro Holdings (ABPO) Profit After Tax (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Profit After Tax data on file, last reported at -$1.0 million in Q1 2026.
- Quarterly Profit After Tax rose 73.55% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33000.0 (up 99.72% YoY) and the FY2025 annual result came in at -$2.9 million, up 60.01% from the prior year.
- Profit After Tax retreated to -$1.0 million in Q1 2026, from $5.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $5.6 million in Q4 2025 to a low of -$14.5 million in Q4 2023.
- A 5-year average of -$1.3 million and a median of -$1.0 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax surged 507.68% — and 2024, when it plunged 4589.67%.
- Tracing ABPO's Profit After Tax over 5 years: stood at $1.5 million in 2022, then plunged by 1097.41% to -$14.5 million in 2023, then jumped by 77.05% to -$3.3 million in 2024, then surged by 269.0% to $5.6 million in 2025, then plunged by 118.24% to -$1.0 million in 2026.
- The last three Profit After Tax figures came in at -$1.0 million (Q1 2026), $5.6 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | -940,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | -1.66 Mn |
| Jun 30, 2025 | -2.98 Mn |
| Mar 31, 2025 | -3.89 Mn |
| Dec 31, 2024 | -3.34 Mn |
| Sep 30, 2024 | -2.09 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Mar 31, 2024 | 636,000.00 |
| Dec 31, 2023 | -14.53 Mn |
| Sep 30, 2023 | -44,630.00 |
| Jun 30, 2023 | 802,803.00 |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 652,421.00 |
| Jun 30, 2022 | -196,919.00 |
| Mar 31, 2022 | -1.03 Mn |